Partnering to diversify and strengthen our product pipeline
Partnerships with pharmaceutical companies may allow us to access additional development and commercial resources, expertise and non-dilutive funding to enable the advancement of a broader and more diverse pipeline. We have selectively established partnerships that enable us to access large commercial indications while leveraging the benefits of those collaborations to expand our internal capabilities. Our pharmaceutical partners include Neurocrine Biosciences; Genentech, a member of the Roche Group; and Flexion Therapeutics.
For more information about partnering with Xenon, please contact:
Robin Sherrington, PhD
Executive Vice President, Strategy & Innovation